Reuters -- Poland’s troubled insulin maker, Bioton BOTN.WA, said on Saturday it had clinched a deal with U.S. investment fund GEM Global Yield Fund on financing worth as much as 363 million zlotys ($117 million). “The agreement guarantees Bioton financing at the level of 200 million zlotys over three years starting with the signature of the deal,” Bioton said in a statement.
